Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans

Circulation

Volumn 122, Issue 2, 2010, Pages 103-105

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Editorials; Inflammation; Myocardial infarction; Remodeling; Rupture

Indexed keywords

CARDIOTROPHIN 1; COLLAGENASE 3; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; MANNOSE BINDING LECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART INFARCTION; APOPTOSIS; CARDIOMEGALY; CELL MEMBRANE; CELL NUCLEUS; CELL STRESS; CELL SURVIVAL; COMPLEMENT LECTIN PATHWAY; DOWN REGULATION; DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE DELETION; GENE DOSAGE; GENETIC TRANSCRIPTION; HEALING; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RUPTURE; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INFLAMMATORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCAR; SIGNAL TRANSDUCTION; STUNNED HEART MUSCLE; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; CYTOKINE RECEPTOR GP130; DOWN-REGULATION; HUMANS; INTERLEUKIN-6; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCYTES, CARDIAC; RUPTURE, SPONTANEOUS; STAT3 TRANSCRIPTION FACTOR; VENTRICULAR REMODELING;

EID: 77954762962     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.969410     Document Type: Editorial

References (18)

1. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395-1403.
2. Frangogiannis NG. Targeting the inflammatory response in healing myo-cardial infarcts. Curr Med Chem. 2006;13:1877-1893.
3. Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99:546-551.
4. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol. 2007;102:393-411. (Pubitemid 47278812)
5. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 1998;14;98:149-156.
6. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, Podewski E, Schieffer B, Rose-John S, Drexler H. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J. 2003;17:2118-2120.
7. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation. 2003;107:798-802.
8. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
9. Ikeda U, Ohkawa F, Seino Y, Yamamoto K, Hidaka Y, Kasahara T, Kawai T, Shimada K. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 1992;24:579-584.
10. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
11. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391-398.
12. Ueda K, Takahashi M, Ozawa K, Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J. 1999;138:908-915. (Pubitemid 29523278)
13. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145-155.
14. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004;95:187-195.
15. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, Yamauchi-Takihara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation. 2001;104:979-981.
16. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther. 2005;107:131-137.
17. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, Fu XY. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 2003;100:12929-12934.
18. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Kishimoto T, Yamauchi-Takihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA. 2000;97:315-319.